FDA Approval
FDA Approved Keytruda for Kidney Cancer Sooner than Expected
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M05-19-NI-001May 02, 2019
Trial Update
Merck Provides Update on Phase 3 KEYNOTE-062 Trial
Merck & Co.
PR-M04-19-NI-085Apr 29, 2019
Accelerated Approval
Merck’s Keytruda to Get Accelerated FDA Evaluation for Treatment of Head and Neck Cancer
Pharma's Almanac
PAO-M02-19-NI-015Feb 19, 2019
Oncology
Positive Results for Keytruda as a Kidney Cancer Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M10-18-NI-028Oct 29, 2018
Clinical Trials
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA®
OncoSec Immunotherapies
PR-M10-18-NI-053Oct 16, 2018
Oncology
EU Gives Nod to KEYTRUDA and Chemotherapy Combination Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-18-NI-009Sep 14, 2018
EMA
European Medicines Agency Adopts Positive Opinion for KEYTRUDA®(pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy
Merck & Co.
PR-M08-18-NI-009Aug 02, 2018
Therapy Approval
KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck & Co.
PR-M07-18-NI-098Jul 30, 2018
Phase III Trial
KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial
Merck & Co.
PR-M07-18-NI-093Jul 27, 2018
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival for Squamous Non-Small Cell Lung Cancer (NSCLC)
Merck & Co.
PR-M05-18-NI-097May 25, 2018
Oncology
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent
Merck & Co.
PR-M04-18-NI-63Apr 18, 2018
Oncology
Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment
Merck & Co.
PR-M01-18-NI-063Jan 22, 2018
Breakthrough Therapy
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy
Eisai
PR-M01-18-NI-032Jan 12, 2018